Michael Mølhøj, Ph.D.

Michael Mølhøj joined Immatics in 2020 and heads the department of CMC Biologics. The department is responsible for all CMC aspects related to the pipeline of bispecific T-cell receptor engaging molecules (TCER^®).

Michael brings 21+ years of Biotech/Pharma R&D experience (GLP/GMP) from leading developability assessments, process developments and analytical activities, to developing advanced bispecifics towards IND/IMPD submission and clinical testing. He has worked for Hoffmann-La Roche (Penzberg, Germany) as technical project leader of T-cell activating bispecific antibodies and mass spectrometry lab head. Prior to Roche, Michael worked for Micromet (now Amgen) and Scil Technology. He is a co-inventor of multiple patents and patent applications related to a range of therapeutic bispecific antibodies, bispecific antibody molecular formats, and analytical methods. Additionally, he has co-authored over 30 publications in international peer-reviewed journals.

Michael holds a Master’s degree and a Ph.D. from the Faculty of Life Sciences at the University of Copenhagen, Denmark.
A proud contributor to approved Faricimab (Vabysmo; VEGF-A-Ang2 CrossMab) and Glofitamab (Columvi; CD20-TCB).